News
29.08.2022
Marinomed Biotech AG continues its growth path and reports strong financials in H1 2022
29.08.2022
Vienna Textile Lab x Kering Material Innovation Lab x ALBINI_next – collaborating towards more sustainable practices in the fashion industry
29.08.2022
Valneva gibt die Auslieferung seines inaktivierten COVID-19 Ganzvirusimpfstoffs in Österreich bekannt
29.08.2022
Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001
25.08.2022
COVID-19-assoziierte Pilzinfektion: Große internationale Studie identifiziert immunologische Mechanismen und klinische Risikofaktoren
25.08.2022
Vast paleogenetic study reveals insights on migration patterns, the expansion of farming and language development from the Caucasus over western Asia and Southern Europe from the early Copper Age until the late middle ages
18.08.2022
Valneva Initiates Rolling Submission of FDA Biologics License Application for its Single-Shot Chikungunya Vaccine Candidate
11.08.2022
Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
10.08.2022
F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Olorofim